Omicron may have higher reinfection risk, but’: 10 things WHO’s latest report reveals

Omicron may have higher reinfection risk, but’: 10 things WHO’s latest report reveals

According to the World Health Organization, the early research suggests that Omicron, the most recent form of the SARS-CoV-2 virus first discovered in South Africa, could readily infect people who have already been infected or have been vaccinated. According to WHO, the sickness will be milder than that caused by the Delta form.

10 Things WHO’s Reports have Revealed In Omicron Infections

  • 1. There have been Omicron cases reported in 57 countries across all WHO regions. At the same time, most of the cases in these nations are currently tied to tourism.
  • 2. According to WHO emergency director Michael Ryan, the variant is efficient in transmitting and likely more efficient than Delta, but that does not mean the virus is unstoppable.
  • 3.Even if it turns out to be less dangerous because it spreads quickly, it could still affect a more significant number of people, putting a strain on the healthcare system.
  • 4.Even if vaccines prove ineffective against Omicron, as some evidence suggests, they should still provide significant protection against severe disease.
  • 5.”More data is needed to establish whether the mutations present on the Omicron variant may result in lower protection from vaccine-derived immunity,” the WHO noted of Omicron’s impact on vaccines.
  • 6.Seroprevalence ranges from 60 to 80 per cent in South Africa, with vaccination coverage hovering around 35 per cent.
  • 7.Even if the severity of Omicron is equal to or possibly lower than that of the Delta variant, WHO states that it is still severe.
  • 8.WHO said all 212 confirmed Omicron cases found in 18 EU countries until December 6 were mild.
  • 9.The WHO cited the European Centre for Disease Prevention and Control’s prediction that the Omicron variant is responsible for 1% of SARS-Cov-2 infections.
  • 10.Even though no severe disease has been reported due to Omicron, WHO predicts that interleukin-6 receptor blockers and corticosteroids will remain effective in treating patients with severe conditions.

Health